Active, Not RecruitingPhase 3Other
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)
Sponsored by Definium Therapeutics US, Inc.
NCT ID
NCT06941844
Target Enrollment
149 participants
Start Date
2025-04-14
Est. Completion
2027-02
About This Study
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Emerge
Conditions Studied
Interventions
- •Placebo
- •DT120
Eligibility
Age:18 Years - 74 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: 1. Diagnosis of MDD per DSM-5 2. Male or female aged 18 to 74 3. Currently experiencing a major depressive episode (MDE) of ≥8 weeks and ≤24 months duration 4. MADRS Total Score ≥26 5. CGI-S Score ≥4 Exclusion Criteria: 1. Certain psychiatric disorders (other than major depressive disorder) 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine 4. Any clinically significant unstable illness
Study Locations (22)
Preferred Research Partners, Inc
Little Rock, Arkansas, United States
Kadima Neuropsychiatry Institute
La Jolla, California, United States
Psychedelic Science Institute
Santa Monica, California, United States
Mountain View Clinical Research, Inc
Denver, Colorado, United States
Clinical Neuroscience Solutions, Inc - Jacksonville
Jacksonville, Florida, United States
Clinical Neuroscience Solutions, Inc - Orlando
Orlando, Florida, United States
Charter Research
Orlando, Florida, United States
Uptown Research Institute (URI), LLC
Chicago, Illinois, United States
Sheppard Pratt
Baltimore, Maryland, United States
Adams Clinical Boston
Boston, Massachusetts, United States
+12 more locations